Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

190.34 USD +0.14 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,187,034
Open 190.43
Bid (Size) 190.01 (1)
Ask (Size) 190.34 (116)
Prev. Close 190.20
Today's Range 185.41 - 191.85
52wk Range 119.29 - 209.72
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)... 
From Business Wire News Releases
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3... 
From Business Wire News Releases

Performance

YTD
+48.59%
+48.59%
1 Month
-3.38%
-3.38%
3 Month
+11.14%
+11.14%
6 Month
+32.04%
+32.04%
1 Year
+43.91%
+43.91%

More News

Read More
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Business Wire News Releases
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
From Business Wire News Releases
Noteworthy Monday Option Activity: CEVA, RGR, ALNY
Tags Stocks
From Market News Video
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
From Business Wire News Releases
Notable Wednesday Option Activity: ALNY, SPOT, EXC
Tags Stocks
From Market News Video
Analyzing Alnylam Pharmaceuticals's Unusual Options Activity
Tags Movers Benzinga Market News
From Benzinga
Why Is Dicerna Stock Getting Slammed Today?
Tags General Short Ideas Health Care
From Benzinga
Stocks To Watch: Alnylam Pharmaceuticals Sees Relative Strength Rating Jump To 91
From Investor's Business Daily
Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday
Tags ALNY Market News DRNA
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.